CORDIS
EU research results

CORDIS

English EN

Chemical Hematology: breaking resistance of hematological malignancies through personalized drug trials

Project information

Grant agreement ID: 727416

Status

Closed project

  • Start date

    1 October 2016

  • End date

    30 September 2017

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 146 668

  • EU contribution

    € 146 668

Hosted by:

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH

Austria

Objective

Personalized medicine aspires to provide optimal therapy in real-time during patient treatment, however current methodology falls short to deliver this in a robust manner. With this in mind, we invented a method for the screening of thousands of drug responses in small samples of an individual’s peripheral blood by automated microscopy and single-cell image analysis. We termed this method pharmacoscopy. In the course of carrying out the i-FIVE ERC grant project plan, we began screening for novel anti-viral or immune modulating drugs. In the quest to increase the physiological relevance of our screening settings, we investigated the possibility of using peripheral blood cells or bone marrow from individuals. We have thus far been able to show that the approach allows for the screening of anti-inflammatory properties of compounds, and to score for distinct sub-population specific cell cytotoxicity profiles of clinical anti-neoplastic agents through the tracking of fluorescent antibodies and probes. Moreover, we have been able to show that the approach empowers the therapeutic decision-making capability of hema-oncologists in a concrete clinical setting using primary myelofibrosis and lymphoma as test diseases. With funding from this grant, we intend to obtain further clinical data through retrospective trials, and incorporate the results into an information package attractive enough to draw the attention of potential investors. We have secured the intellectual property rights and have assembled the know-how required to enable commercialization efforts. With the unique image-based single cell analysis of human liquid tissues, we believe that chemos has the potential to develop into a service that enables and advances personalized medicine and drug discovery for a broad spectrum of hematological disorders.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH

Address

Lazarettgasse 14 Akh Bt 25.3
1090 Wien

Austria

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 146 668

Beneficiaries (1)

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH

Austria

EU Contribution

€ 146 668

Project information

Grant agreement ID: 727416

Status

Closed project

  • Start date

    1 October 2016

  • End date

    30 September 2017

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 146 668

  • EU contribution

    € 146 668

Hosted by:

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH

Austria